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Abstract
Background: The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling
pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both
tumorigenesis and activation of immune responses. In diffuse large B-cell lymphoma (DLBCL), the transcription
factor STAT3 has been associated with aggressive disease phenotype and worse overall survival. While multiple
therapies inhibit upstream signaling, there has been limited success in selectively targeting STAT3 in patients.
Antisense oligonucleotides (ASOs) represent a compelling therapeutic approach to target difficult to drug
proteins such as STAT3 through of mRNA targeting. We report the evaluation of a next generation STAT3 ASO
(AZD9150) in a non-Hodgkin’s lymphoma population, primarily consisting of patients with DLBCL.
Methods: Patients with relapsed or treatment refractory lymphoma were enrolled in this expansion cohort. AZD9150
was administered at 2 mg/kg and the 3 mg/kg (MTD determined by escalation cohort) dose levels with initial loading
doses in the first week on days 1, 3, and 5 followed by weekly dosing. Patients were eligible to remain on
therapy until unacceptable toxicity or progression. Blood was collected pre- and post-treatment for analysis of
peripheral immune cells.
Results: Thirty patients were enrolled, 10 at 2 mg/kg and 20 at 3 mg/kg dose levels. Twenty-seven patients
had DLBCL. AZD9150 was safe and well tolerated at both doses. Common drug-related adverse events
included transaminitis, fatigue, and thrombocytopenia. The 3 mg/kg dose level is the recommended phase 2
dose. All responses were seen among DLBCL patients, including 2 complete responses with median duration
of response 10.7 months and 2 partial responses. Peripheral blood cell analysis of three patients without a
clinical response to therapy revealed a relative increase in proportion of macrophages, CD4+, and CD8+ T
cells; this trend did not reach statistical significance.
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Conclusions: AZD9150 was well tolerated and demonstrated efficacy in a subset of heavily pretreated patients with
DLBCL. Studies in combination with checkpoint immunotherapies are ongoing.
Trial registration: Registered at ClinicalTrials.gov: NCT01563302. First submitted 2/13/2012.
Keywords: STAT3, Anti-sense oligonucleotide, Diffuse large B-cell lymphoma, DLBCL, Clinical trial, Immunotherapy,
Lymphoma, JAK-STAT
Background
The Janus kinases (JAKs) and signal transducer and activa-
tor of transcription (STAT) proteins are components of an
intracellular cascade pathway that plays an important role
in cancer. The JAK/STAT pathway was first recognized
through its association with interferons α/γ and interleu-
kins (IL) [1–3]. The downstream effect of cell-surface-level
activation of the JAK/STAT pathway is a gene expression
profile that results in enhanced cell survival, immune cell
activation, and oncogenesis [4]. Increasing evidence sup-
ports the role of the JAK/STAT pathway in oncogenesis in
both solid and hematologic malignancies [5, 6]. Significant
interest has been directed toward understanding how the
function or dysfunction of the JAK/STAT pathway contrib-
utes to oncogenic transformation and cancer cell survival
[7–9]. Preclinical data suggest that aberrant activation of
this pathway contributes to tumorigenesis [10] and to
clonality and survival of cancer stem cells [11]. Targeting
the JAK/STAT pathway can inhibit its downstream gene
activation [12] and can suppress tumor growth [13, 14].
STAT3 is activated by phosphorylation of tyrosine
residues by members of the JAK family recruited to the
cytoplasmic portion of cell surface receptors, which are ac-
tivated by growth factors and cytokines [2]. Phosphorylated
STAT3 dimerizes and is translocated from the cytoplasm
to the nucleus, where the dimer acts as a transcription fac-
tor for signals involved in cell proliferation, development,
and differentiation and in inflammation and apoptosis.
Constitutive activation of STAT3 is found in several types
of human tumors [15, 16]. Hyperactivity of upstream
growth factor receptors or non-receptor tyrosine kinases
(e.g., Src, JAK, or Abl) or overexpression of stimulating li-
gands (e.g., epidermal growth factor receptor or IL-6) can
produce a persistent STAT3 signal [17]. Constitutively
active STAT3 has been shown to increase levels of
tumor-associated signaling molecules such as survivin,
Bcl-XL, cyclin D1/D2, C-Myc, Mcl-1, and vascular
endothelial growth factor (VEGF), leading to in-
creased cell proliferation, cell survival, angiogenesis,
and oncogenesis [18–20].
STAT3 signaling also plays an important role in the
regulation of the cancer stromal and immune cells of the
tumor microenvironment. Ablation of STAT3 in the
hematological compartment in a murine inducible
knockout model improved the antitumor effect of neutro-
phils and natural killer cells, while depleting regulatory
T-cells, suggesting that STAT3 signaling has a broad effect
on multiple hematological compartments [21]. This en-
hancement of immune effectors resulting from STAT3 de-
pletion could be mediated, in part, through enhancement
of the antigen presentation capacity and co-stimulatory
activation of dendritic cells. Multiple lines of evidence in-
dicate that reversal of STAT3-mediated immunosuppres-
sion has the potential to augment the antitumor immune
response [22]. Taken together, STAT3 is a particularly
attractive cancer target as it not only regulates the expres-
sion of many genes that contribute directly to the survival
and proliferation of tumor cells, but also supports
immune-suppressive stromal cells within the tumor
microenvironment, promoting tumor immune evasion,
angiogenesis, and metastasis [23].
AZD9150 (ISIS 481464) is a 16-nucleotide next gen-
eration chemistry antisense oligonucleotide [24] de-
signed to target and indirectly downregulate expression
of human STAT3 protein by downregulating STAT3
mRNA. Preclinical activity has been shown in cell line
and PDX lymphoma xenograft models, and initial
single-agent studies of AZD9150 demonstrate its effi-
cacy and clinical safety in patients with refractory
lymphoma and lung cancer [25]. Here, we present the
not previously reported results of a phase Ib expansion
of the clinical trial of AZD9150 in patients with refrac-
tory/relapsed lymphoma. The primary goal of this
expansion cohort was to assess safety, with exploratory
endpoints investigating efficacy and immune cell
changes among patients.
Methods
Patients
Eligible patients in the expansion cohort had a histo-
logically confirmed lymphoma that had relapsed or
became refractory after administration of at least 1 line
of therapy and for which no standard therapy existed.
Other eligibility requirements included age ≥ 18 years
at enrollment, measurable disease per RESIST 1.1 cri-
teria, Eastern Cooperative Oncology Group (ECOG)
performance status ≤2, and life expectancy of at least
12 weeks. Willingness to provide pre- and post-treatment
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tumor tissue specimens was also required. Exclusion
criteria included baseline cytopenias, significant cardiovas-
cular disease, hepatic or renal dysfunction, known brain
metastases, or prior concurrent malignancy in the past
3 years. Patients receiving ongoing anticoagulant therapy
were also excluded. The clinical trial was reviewed and ap-
proved by the institutional IRB and compliant with human
subject ethics guidelines. Informed consent was obtained
from all patients prior to study enrollment. The trial was
registered at www.clinicaltrials.gov as NCT01563302.
Study design
The study was a phase I/Ib, multicenter, open-label
study with a 3 + 3 dose-escalation design and a pre-
planned dose expansion cohort. All patients received
AZD9150, an ASO STAT3 inhibitor, as a single agent.
In cycle 0, a loading regimen of AZD9150 was delivered
intravenously at a given dose level with administration
on Days 1, 3, and 5. Subsequently, in cycles 1 and
beyond, a maintenance dose was administered weekly
until disease progression, unacceptable toxicity, or pa-
tient discontinuation for any reason. The initial cohort
of patients received 2 mg/kg AZD9150. Escalation of
dose in this cohort was allowed based on initial toxicity
and pharmacokinetic data from the dose escalation co-
hort. The decision to increase the dose to 3 mg/kg was
made on the basis of safety data collected during cycle
0 (1 week) and cycle 1 (3 weeks). The decision not to
pursue a higher dose was based on thrombocytopenia
observed during dose escalation.
All patients were monitored clinically and with
weekly blood tests to characterize the safety of
AZD9150 and to assess preliminary evidence of clinical
activity. Imaging was performed with CT or MRI of
measurable sites and restaging imaging occurred every
8 weeks within a 7-day window. The recommended
phase 2 dosing was selected on the basis of the toxic-
ities observed in the first 28 days of dosing and prelim-
inary evidence of clinical activity. Patients were
enrolled in the expansion cohort with a goal of approxi-
mately 25 evaluable patients, defined as patients who
completed the first restaging scan and underwent both
pre- and post-treatment biopsies.
Endpoints
The primary endpoint of the expansion cohort was to
evaluate the safety and determine the recommended Phase
2 dose (RP2D) in advanced lymphoma. Secondary objec-
tives included measuring clinical activity of AZD9150. This
included objective response rate, defined as the percentage
of patients with complete response (CR) or partial response
(PR) as the best response. For this purpose, disease burden
was evaluated according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST) version 1.1 for solid
tumors or the International Workshop Response Criteria
(IWRC) for Non-Hodgkin’s Lymphoma. Responses were
confirmed using IWRC [ref]. Additional secondary efficacy
endpoints included clinical benefit rate, defined as the per-
centage of patients with CR, PR, or stable disease (SD) for
more than 4 months as the best response; progression-free
survival duration; and duration of response for responding
patients, defined as the time from the date of the first ob-
jective status assessment of CR or PR to the date of disease
progression. Results of changes in myeloid cell populations
of peripheral blood mononuclear cells (PBMCs) were pre-
sented as absolute changes and percentage changes from
baseline over time after study drug administration.
Safety assessments, including clinical assessment,
toxicity monitoring, and blood testing were conducted
for all patients in the expansion arm on a weekly basis.
At any time, if 33% or more of the participants experi-
enced a dose-limiting toxicity within the monitoring
window, enrollment was held and resumed at the next
lowest dose level. All patients who enrolled were
accounted for in a patient disposition analysis. All
patients who received any part of a dose of the study
treatment were included in the full analysis population.
This population was the basis for all data on demographic
and baseline disease characteristics and clinical activity.
Adverse events
Adverse events (AEs) occurring from study day 1 until
4 weeks after the last dose of AZD9150 were recorded
and graded using the adult National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE, version 4.0). AE terms were coded using the
most current version of the Medical Dictionary for
Regulatory Activities (MedDRA). The incidence of all
treatment-emergent AEs was summarized by system,
organ, class, and preferred term. Investigators catego-
rized AEs as being at least possibly related to AZD9150
or unrelated. AEs reported as being related to
AZD9150 were classified as treatment-related AEs.
Tissue procurement and NGS
For pre-treatment biopsy samples either fresh or arch-
ival tissue was used, however tissue had to have been
obtained within 28 days of first dose. The post dose bi-
opsy timing was determined on a per patient basis
based on response. All tissue was obtained via needle
biopsy conducted by an interventional radiologist and
at least 3 cores were obtained at each time point. All
samples were fixed in formalin and paraffin embedded
and sent to the sponsor for analysis.
Genomic analysis was performed using a clinical NGS-
based assay (FoundationOne™Heme, Foundation Medi-
cine Inc., Cambridge, MA) as previously described [26].
The sequencing method was validated on hybridization
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captured, adaptor ligation-based libraries using DNA
extracted from ten formalin-fixed paraffin-embedded
(FFPE) sections cut at 5 μm [26]. Adaptor-ligated
sequencing libraries were captured by solution
hybridization with two custom bait-sets targeting 374
cancer-related genes, 31 genes frequently rearranged by
DNA-seq and 265 genes frequently rearranged by
RNA-seq. This method was validated also for the detec-
tion of copy number alterations, including amplification
and deletions, by a statistical model normalized to ex-
onic coverage and allele frequencies.
Peripheral blood procurement and analysis
PBMCs were collected from 4 patients both before
treatment and at the completion of each cycle of ther-
apy. Each sample was separated by gradient centrifuga-
tion, and the mononuclear cells were collected and
processed for flow cytometry. Following density gradi-
ent separation, samples were fixed using the Foxp3/
Transcription Factor Staining Buffer Set (eBioscience)
and then stained with up to 16 antibodies at a time
from Biolegend, BD Biosciences, eBioscience, and Life
Technologies. Flow cytometry data was collected on a
custom 5-laser, 18-color BD LSR II cytometer and ana-
lyzed using FlowJo Version 7.6.5 (Treestar).
Results
Patient characteristics
Thirty-three lymphoma patients were enrolled at 9
sites in the United States. Of these patients, 30 re-
ceived at least 1 infusion of AZD9150 between Febru-
ary 27, 2012 and November 20, 2014 (Table 1). Data
for all patients is current as of cutoff of July 2016. All
patients had histologically confirmed lymphoma, 27
patients had DLBCL, 2 had follicular lymphoma, and 1
had Hodgkins lymphoma. The median age of partici-
pants was 69 years, and most (93%) had an ECOG per-
formance status of 1 or better. The majority of patients
(80%) had stage III or IV disease. All patients had
received prior systemic therapies for their cancer. The
median number of prior treatment regimens was 4
(range, 1–9). About a third of the patients had received
prior radiation therapy, and 20% had received prior
surgery for their disease. Approximately 27% of
patients had a previous cancer diagnosis.
Treatment duration and toxicities
Patients received a median of 2 cycles of AZD9150
(range, 1–21). Five patients received 4 or more cycles
of therapy. The most common reason for discontinuing
treatment was disease progression (27 patients, 75%).
Treatment was terminated among the remaining pa-
tients for the following reasons: 5 (14%) voluntarily
withdrew consent, 1 (3%) withdrew at recommendation
of investigator, 1 (3%) due to ineligibility, and 2 (6%) for
other reasons. No patient withdrew from the study be-
cause of toxicities related to AZD9150. The pattern and
frequency of AEs was not significantly different be-
tween dose levels.
Of the 30 patients treated with at least 1 dose of
AZD9150, 29 experienced at least 1 AE (Table 2). The
most common drug-related AEs in patients were transami-
nitis (alanine transaminase or aspartate transaminase eleva-
tion, 40%), fatigue (37%), thrombocytopenia (30%), nausea
(20%), and anemia, hypomagnesemia, and peripheral
edema (each 17%). The majority of reported toxicities were
grade 1 or 2, however higher-grade thrombocytopenia was
more common with 3 grade 3 and 2 grade 4 events. Eight-
een patients (60%) experienced at least one grade 3 or
higher AE and 5 (17%) had events that were at least
possibly therapy-related. One patient died from acute
respiratory failure while participating in the study;
this death resulted from underlying comorbidities and
was not related to the patient’s participation in the
study or to the study drug.
Antitumor activity
All 30 patients who received at least 1 dose of AZD9150
were assessed for response to treatment. The percent
change in tumor size during treatment is presented as a
spider plot in Fig. 1. All responses were observed among
patients with DLBCL. Two (7%) patients had a CR to
Table 1 Patient demographics and baseline clinical
characteristics by dose level
Characteristic 2 mg/kg
(n = 10)
3 mg/kg
(n = 20)
Median age, y (range) 69 (23–83) 65 (22–81)
Male, n (%) 8 (80) 10 (50)
White, n (%) 8 (80) 20 (100)
ECOG performance status, n (%)
0 4 (40) 3 (15)
1 6 (60) 15 (75)
2 2 (10)
Disease stage, n (%)
I 0 2 (10)
II 1 (10) 3 (15)
III 4 (40) 3 (15)
IV 5 (50) 12 (60)
Prior treatment with radiation therapy, n (%) 3 (30) 6 (30)
Prior treatment with systemic therapy, n (%) 10 (100) 20 (100)
Median number of prior regimens (range) 4.5 (1–8) 3.5 (1–9)
Prior treatment with surgery, n (%) 3 (30) 3 (15)
History of cancer(s) other than current
cancer, n (%)
5 (50) 3 (15)
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therapy: 1 each at the 2 mg/kg and 3 mg/kg dose levels.
The median duration of response at data cutoff was
10.7 months; however, one response was ongoing at last
follow-up. Two (7%) patients had a PR to therapy at initial
restaging. One progressed clinically and the other pro-
gressed on subsequent restaging after 5 months of therapy.
One (3%) patient had SD as the best response. A total of 4
patients, all with DLBCL, had PR, CR, or SD for at least
4 months, for a clinical benefit rate of 13%. There was no
clear difference in progression-free survival or objective re-
sponse rate between the 2 dose levels (Fig. 2).
Mutational analysis of responder
A pretreatment biopsy specimen was obtained for the pa-
tient who demonstrated a persistent complete response to
therapy. Genomic analysis identified the following muta-
tions (percent-reads, coverage): a known somatic
short-variant, CD79B_c.587A>C_p.Y196S (0.34,604), a
likely somatic short-variant, BCL10_c.657_699delTGAG
ATGTTTCTTCCCTTAAGATCACGTACTGTTTCACG
ACAA_p.E220fs*1+ (0.23,474), and homozygous deletions
of CDKN2A and CDKN2B in 5 of 5 exons. Other
mutations of interest were identified in CCND3,
FOXP1, IRF4, PCLO, and a rearrangement of BCL6/
FOXP1 (full list in appendix 1).
Changes in PBMCs
Peripheral blood was collected from 4 patients prior to
and on treatment including 1 at 2 mg/kg and 3 at
3 mg/kg dose levels. Three of the patients completed
Cycle 1 and then ceased treatment because of disease
progression, and the remaining patient completed Cy-
cles 1 and 2 (Fig. 3a). The PBMC populations of the
latter patient showed clear evidence of peripheral
immunomodulation by AZD9150, with 5-fold down-
regulation of granulocytic myeloid-derived suppressor
cells (Gr-MDSCs; CD11b+CD33+CD15+HLA-DR−/low)
and a greater than 1.5-fold upregulation of macro-
phages (CD11b+CD33−), CD4+ effector T cells, and
CD8+ T cells (Fig. 3b). In addition, this patient’s circu-
lating DLBCL tumor cell frequency decreased more
than 6-fold, from 10.2 to 1.7% of PBMCs. Of the 3 pa-
tients who received a single cycle of therapy, the
PBMC profiles of 2 resembled that of the previously
described patient (Fig. 3c), whereas the third showed
increases in Gr-MDSCs and circulating tumor cell fre-
quency and decreases in effector CD4+ and CD8+ T-
cell frequencies (Fig. 3d). This patient’s PBMCs be-
came dominated by an expanded macrophage popula-
tion after the first cycle of therapy.
Discussion
In this trial of the next-generation STAT3 ASO,
AZD9150 in patients with DLBCL, the drug was well
tolerated at doses of 2 or 3 mg/kg weekly. No signifi-
cant AEs associated with AZD9150 led to unacceptable
toxicity or early discontinuation of therapy in the study
population. We observed a clinical benefit in 13% of
the study population of patients with heavily pre-
treated DLBCL. Among both patients with a CR, the
response was durable, lasting nearly 11 months in 1
patient and is currently ongoing in the other. Corollary
PBMC analysis shows changes in relevant T cell popu-
lations with therapy.
Activated STAT3 plays an established role in cancer
cell survival, and suppressed levels of phosphorylated
STAT3 have shown to correlate with better patient sur-
vival in lymphoma. We have previously reported the ef-
ficient uptake and STAT3 knockdown capacity of
Table 2 Adverse events experienced by at least 10% of patients
by severity
AE, n (%) Total
(N = 30)
Grade 1 Grade 2 Grades 3
and 4
Any AE, highest grade
experienceda
29 (97) 2 (7) 8 (27) 18 (60)
ALT elevation 12 (40) 5 (17) 5 (17) 2 (7)
AST elevation 12 (40) 7 (23) 4 (13) 1 (3)
Fatigue 11 (37) 4 (13) 5 (17) 2 (7)
Thrombocytopenia 9 (30) 2 (7) 2 (7) 5 (17)
Nausea 6 (20) 2 (7) 3 (10) 1 (3)
Anemia 5 (17) 2 (7) 2 (7) 1 (3)
Hypomagnesemia 5 (17) 5 (17) 0 0
Peripheral edema 5 (17) 3 (10) 2 (7) 0
Alkaline phosphatase
elevation
4 (13) 3 (10) 1 (3) 0
Dysphagia 4 (13) 3 (10) 0 1 (3)
Dyspnea 4 (13) 2 (7) 2 (7) 0
Hypercalcemia 4 (13) 1 (3) 2 (7) 1 (3)
Hypokalemia 4 (13) 3 (10) 0 1 (3)
Hyponatremia 4 (13) 3 (10) 0 1 (3)
Neutropenia 4 (13) 1 (3) 0 3 (10)
Vomiting 4 (13) 4 (13) 0 0
Abdominal pain 3 (10) 1 (3) 2 (7) 0
Anorexia 3 (10) 1 (3) 2 (7) 0
Asthenia 3 (10) 1 (3) 1 (3) 1 (3)
Constipation 3 (10) 3 (10) 0 0
Creatinine elevated 3 (10) 2 (7) 1 (3) 0
Diarrhea 3 (10) 3 (10) 0 0
Upper respiratory tract
infection
3 (10) 1 (3) 2 (7) 0
Urinary tract infection 3 (10) 1 (3) 2 (7) 0
Abbreviations: AE adverse event, AST aspartate transaminase, ALT
alanine transaminase
aIncludes one patient who died of acute respiratory failure (Grade 5 AE)
unrelated to the study medication while on trial
Reilley et al. Journal for ImmunoTherapy of Cancer           (2018) 6:119 Page 5 of 10
AZD9150 in patient-derived tumor explant models of
lymphoma [25]. The results of the current study dem-
onstrate that this next-generation ASO-mediated re-
duction of STAT3 mRNA levels in humans is both a
feasible and an effective strategy for treating
advanced-stage DLBCL. An important finding is that
this therapy was well tolerated, confirming our early
phase 1 results [25]. The majority of the patients had
undergone several lines of therapy—a median of 4—for
their current cancer. Notably, over one quarter of the
patients had a prior diagnosis of cancer, and may in fact
have received even more systemic therapies. Patients
withdrew from the study in most cases because of clin-
ical deterioration unrelated to AZD9150 treatment or be-
cause of disease progression. Overall, our results suggest
that AZD9150 therapy would likely be well tolerated and
have meaningful clinical activity at a dose of 3 mg/kg in
the broader population of patients with DLBCL.
Among activated B-cell (ABC) type DLBCL there is
evidence of increased JAK-STAT and pSTAT3
Fig. 2 Waterfall plot of best responses seen in 24 evaluable patients. Blue dotted lines are reference for partial response (− 30%) and
progressive disease (+ 20%)
Fig. 1 Spider plot of percentage change in tumor size during treatment
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activation [27]. Comprehensive genomic analysis was
performed in the pretreatment biopsy specimen of a
patient who experienced a complete response of
therapy. Multiple known pathogenic mutations were
identified including in CD79B, ERBB2, RET, and
homozygous deletions in tumor suppressors CDKN2A/
B (Additional file 1: Table S1). CD79B is a subunit of the
B-cell-receptor (BCR) and has been implicated as an
oncogenic driver, primarily in activated B-cell (ABC)
DLBCL, through mutations that lead to a chronically ac-
tive state [28]. In this patient, we hypothesize that combin-
ation of multiple activating mutations and loss of tumor
suppressors contributed to tumor progression through
over-activation of the JAK-STAT pathway; and was effect-
ively suppressed through direct targeting of STAT3. Given
the recognized over-activation of JAK-STAT signaling in
advanced ABC-type DLBCL, the mechanism of anti-
tumor effect of STAT targeting therapy should be further
investigated in future studies. Additionally, NK/T-cell
lymphomas can be driven by activation of STAT3 [29]
and may be rationale diseases to target with STAT
inhibition [30, 31].
In the peripheral blood, we observed increases in the
both lymphoid and myeloid cell populations. In three
of four patients, this resulted in a favorable shift with
increased CTLs and decreased MDSCs. While the
numbers of patients analyzed was too small for cor-
relative analysis, the consistent pattern of Gr-MDSC
and DLBCL cell downregulation in the context of
macrophage and CD4+ and CD8+ effector T-cell upreg-
ulation suggests a possible pharmacologic biomarker
signature of response to STAT3 ASO treatment. These
findings are consistent with recently presented data
demonstrating the ability of a murine specific STAT3
ASO to suppress CD163 and Arginase in macrophages
in the tumor microenvironment of syngeneic tumor
models [32]. The role of regulatory T cells and re-
sponse to therapy is potentially relevant, however we
did not observe a clear trend in our data (Add-
itional file 2: Figure S1). In follicular lymphoma, there
is evidence that TGF-β induces CD70 on T-cells lead-
ing to an exhausted phenotype that is associated with
worse patient outcomes [33]. The ability to reduce im-
munosuppressive cells in the microenvironment may
Fig. 3 Changes in patient PBMC profiles following AZD9150 therapy (PBMC subpopulations with frequencies of less than 2% are not shown). a
Surface markers analyzed. b-e Patient PBMC populations before (blue) and after 1 (orange) or 2 (green) cycles of therapy
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synergize with therapies that enhance cytotoxic lym-
phocytes. One limitation of this study is a lack of
PBMC data from patients with persistent clinical re-
sponses and this analysis would be of certain value in
future studies.
Emerging evidence shows that many T-cell immune re-
sponses are limited by the development of a suppressive
myeloid phenotype [34, 35]. Adding therapies that target
MDSCs may improve the efficacy of existing immuno-
therapies. For instance, tumor-induced VEGF acts
through JAK/STAT signaling to induce MDSCs with
immunosuppressive functionality [36]. Interestingly,
genetic inhibition of STAT3 function has been shown
to reduce the immunosuppressive capability of MDSCs,
even in the setting of co-stimulatory signaling that re-
sults in expansion of the MDSC population [37]. Taken
together, this suggests further efforts are need to better
characterize myeloid subpopulations before and as a
consequence of therapy.
Conclusions
In conclusion, the results of this clinical trial provide evi-
dence that AZD9150, a next-generation ASO inhibitor of
STAT3 mRNA, is safe and appears to benefit some pa-
tients with heavily pretreated DLBCL. Given the clear evi-
dence of accumulation of ASO and suppression of STAT3
in the tumor microenvironment [25], it is likely that
AZD9150 is exerting a positive immunomodulatory effect
and clinically meaningful antitumor activity. Trials to
combine this agent with checkpoint-targeting immuno-
therapies are in progress.
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Abbreviations
ABC: Activated B-cell; AE: Adverse event; ASO: Anti-sense oligonucleotide;
BCR: B-cell receptor; CR: Complete response; CT: Computed tomography;
CTCAE: Common terminology criteria for adverse events; DLBCL: Diffuse
large B-cell lymphoma; ECOG: Eastern cooperative oncology group;
FFPE: Formalin-fixed paraffin-embedded; IL: Interleukin; JAK: Janus kinase;
MDSC: Myeloid-derived suppressor cells; MedDRA: Medical dictionary for
regulatory activities; MRI: Magnetic resonance imaging; mRNA: Messenger
ribonucleic acid; MTD: Max tolerated dose; NGS: Next-generation sequencing;
PBMC: Peripheral blood mononuclear cell; PR: Partial response;
RECIST: Response evaluation criteria in solid tumors; RNA: Ribonucleic acid;
RP2D: Recommended phase 2 dose; SD: Stable disease; STAT: Signal
transduction and activation of transcription; VEGF: Vascular endothelial
growth factor
Acknowledgments
The authors would like to thank the Department of Scientific Publications at
MD Anderson Cancer Center for their review of the manuscript. We would
like to thank the patients and research staff that made this trial possible.
Funding
This study was sponsored by AstraZeneca.
Availability of data and materials
The datasets used and/or analyzed during the current study available from the
corresponding author on reasonable request.
Authors’ contributions
PM, CC, PL, YK, TZ, JS, MJ, SJL, MY, SGH, MVPN, XX, JH, AR, BPM, ARM, and
DSH contributed to the development of AZD9150 and designed the trial.
DSH, RK, AY, JN, NF, LF, and SP-P participated in the enrollment and care of
patients on trial. MJR, MC, QL, DSH directed the collection and analysis of
immune correlates. MJR, PM, CC, PL, and DSH were responsible for data
collection and analysis. MJR and DH wrote the manuscript. All authors read
and approved the final manuscript.
Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board at
the University of Texas MD Anderson Cancer Center. Written informed consent
was obtained from the patients prior to treatment.
Consent for publication
Written informed consent was obtained from the patients for publication
of their individual details and accompanying images in this manuscript.
The consent form is held by the authors and is available for review by
the Editor-in-Chief.
Competing interests
PM, CC, PL, RW, and MVPN are employees of Astrazeneca. YK, TZ, JS, MJ, SJL,
MY, SGH, XX, JH, AR, BPM, and ARM are employees of Ionis Pharmaceuticals.
The remaining authors declare no potential conflicts of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Division of Hematology/Oncology, University of Virginia Health System,
Charlottesville, VA, USA. 2Oncology, IMED Biotech Unit, AstraZeneca
Pharmaceuticals, Waltham, MA, USA. 3UC San Diego Moores Cancer Center,
La Jolla, CA, USA. 4Department of Antisense Drug Discovery, Ionis
Pharmaceuticals, Inc., Carlsbad, CA, USA. 5Memorial Sloan Kettering Cancer
Center, New York, NY, USA. 6Mary Crowley Cancer Research Center, Dallas,
TX, USA. 7Department of Investigational Cancer Therapeutics, The University
of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0455,
Houston, TX 77030, USA. 8Drug Safety and Metabolism, IMED Biotech Unit,
AstraZeneca Pharmaceuticals, Waltham, MA, USA.
Received: 12 July 2018 Accepted: 28 October 2018
References
1. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins.
Science [Internet]. 1994;264(5164):1415–21 Available from: http://www.ncbi.
nlm.nih.gov/pubmed/8197455. [cited 21 Nov 2017].
2. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by
tyrosine phosphorylation in response to epidermal growth factor and
interleukin-6. Science [Internet]. 1994;264(5155):95–8 Available from: http://
www.ncbi.nlm.nih.gov/pubmed/8140422. [cited 21 Nov 2017].
3. Lütticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, et
al. Association of transcription factor APRF and protein kinase Jak1 with the
interleukin-6 signal transducer gp130. Science [Internet]. 1994;263(5143):89–
92 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8272872. [cited 21
Nov 2017].
Reilley et al. Journal for ImmunoTherapy of Cancer           (2018) 6:119 Page 8 of 10
4. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a
leading role for STAT3. Nat Rev Cancer [Internet]. 2009;9(11):798–809
Available from: http://www.nature.com/doifinder/10.1038/nrc2734. [cited 21
Nov 2017].
5. Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, et al.
Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome
in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg [Internet].
2013;17(5):887–98 Available from: http://link.springer.com/10.1007/s11605-
013-2168-7. [cited 21 Nov 2017].
6. Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT
pathway activation in malignant and nonmalignant cells contributes to
MPN pathogenesis and therapeutic response. Cancer Discov [Internet]. 2015;
5(3):316–31 Available from: http://cancerdiscovery.aacrjournals.org/cgi/doi/
10.1158/2159-8290.CD-14-0736. [cited 21 Nov 2017].
7. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their
impact on cellular function. Oncogene [Internet]. 2000;19(21):2468–73
Available from: http://www.nature.com/articles/1203476. [cited 21 Nov 2017].
8. Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat
Rev Cancer [Internet]. 2004;4(2):97–105 Available from: http://www.nature.
com/doifinder/10.1038/nrc1275. [cited 21 Nov 2017].
9. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the
emerging role of signal transducers and activators of transcription in cancer.
Nat Clin Pract Oncol [Internet]. 2005;2(6):315–24 Available from: http://www.
nature.com/doifinder/10.1038/ncponc0195. [cited 21 Nov 2017].
10. Woodfield SE, Graves HK, Hernandez JA, Bergmann A. De-regulation of JNK
and JAK/STAT signaling in ESCRT-II mutant tissues cooperatively contributes
to neoplastic tumorigenesis. Singh SR, editor. PLoS One [Internet]. 2013;8(2):
e56021 Available from: http://dx.plos.org/10.1371/journal.pone.0056021.
[cited 21 Nov 2017].
11. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-
STAT blockade inhibits tumor initiation and clonogenic recovery of prostate
cancer stem-like cells. Cancer Res [Internet]. 2013;73(16):5288–98 Available
from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-13-
0874. [cited 21 Nov 2017].
12. McCann GA, Naidu S, Rath KS, Bid HK, Tierney BJ, Suarez A, et al.
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer,
using a novel STAT3 inhibitor. Oncoscience [Internet]. 2014;1(3):216–28
Available from: http://impactjournals.com/oncoscience/index.php?abs=26.
[cited 21 Nov 2017].
13. Kowshik J, Baba AB, Giri H, Deepak Reddy G, Dixit M, Nagini S. Astaxanthin
inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and
angiogenesis in a hamster model of oral cancer. Singh SR, editor. PLoS One
[Internet]. 2014;9(10):e109114 Available from: http://dx.plos.org/10.1371/
journal.pone.0109114. [cited 21 Nov 2017].
14. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, et al. JAK
kinase inhibition abrogates STAT3 activation and head and neck squamous
cell carcinoma tumor growth. Neoplasia [Internet]. 2015;17(3):256–64
Available from: http://linkinghub.elsevier.com/retrieve/pii/
S1476558615000147. [cited 21 Nov 2017].
15. Liu Y, Li P-K, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-
apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem [Internet].
2010;285(35):27429–39 Available from: http://www.jbc.org/lookup/doi/10.
1074/jbc.M110.142752. [cited 21 Nov 2017].
16. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, et al.
Constitutively activated Stat3 induces tumorigenesis and enhances cell
motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol
[Internet]. 2007;27(12):4444–53 Available from: http://mcb.asm.org/cgi/doi/
10.1128/MCB.02404-06. [cited 21 Nov 2017].
17. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative
signaling through the signal transducer and activator of transcription 3 and
nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma.
Blood [Internet]. 2008;111(7):3701–13 Available from: http://www.ncbi.nlm.
nih.gov/pubmed/18160665. [cited 21 Nov 2017].
18. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al.
Constitutive activation of signal transducers and activators of transcription 3
correlates with cyclin D1 overexpression and may provide a novel
prognostic marker in head and neck squamous cell carcinoma. Cancer Res
[Internet]. 2002;62(12):3351–5 Available from: http://www.ncbi.nlm.nih.gov/
pubmed/12067972. [cited 21 Nov 2017].
19. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors
provides novel molecular targets for therapeutic intervention. Clin Cancer
Res [Internet]. 2002;8(4):945–54 Available from: http://www.ncbi.nlm.nih.gov/
pubmed/11948098. [cited 21 Nov 2017].
20. Danoch H, Kalechman Y, Albeck M, Longo DL, Sredni B. Sensitizing B- and
T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via
Inhibition of the VLA-4-IL10-Survivin Axis. Mol Cancer Res [Internet]. 2015;
13(3):411–22 Available from: http://mcr.aacrjournals.org/cgi/doi/10.1158/
1541-7786.MCR-14-0459. [cited 21 Nov 2017].
21. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al.
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med [Internet]. 2005;11(12):1314–
21 Available from: http://www.nature.com/doifinder/10.1038/nm1325. [cited
21 Nov 2017].
22. Li HS, Liu C, Xiao Y, Chu F, Liang X, Peng W, et al. Bypassing STAT3-
mediated inhibition of the transcriptional regulator ID2 improves the
antitumor efficacy of dendritic cells. Sci Signal [Internet]. 2016;9(447):ra94
Available from: http://stke.sciencemag.org/cgi/doi/10.1126/scisignal.aaf3957.
[cited 21 Nov 2017].
23. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic
cancer-associated stellate cells promote differentiation of myeloid-derived
suppressor cells in a STAT3-dependent manner. Cancer Res [Internet]. 2013;
73(10):3007–18 Available from: http://cancerres.aacrjournals.org/cgi/doi/10.
1158/0008-5472.CAN-12-4601. [cited 21 Nov 2017].
24. Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, et
al. Synthesis and biophysical evaluation of 2′,4′-constrained 2’O-
methoxyethyl and 2′,4′-constrained 2’O-ethyl nucleic acid analogues. J
Org Chem [Internet]. 2010;75(5):1569–81 Available from: http://pubs.
acs.org/doi/abs/10.1021/jo902560f. [cited 21 Nov 2017].
25. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, et al.
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3
with early evidence of clinical activity in lymphoma and lung cancer. Sci
Transl Med [Internet]. 2015;7(314):314ra185 Available from: http://stm.
sciencemag.org/cgi/doi/10.1126/scitranslmed.aac5272. [cited 21 Nov 2017].
26. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al.
Development and validation of a clinical cancer genomic profiling test
based on massively parallel DNA sequencing. Nat Biotechnol [Internet].
2013;31(11):1023–31 Available from: http://www.ncbi.nlm.nih.gov/pubmed/
24142049. [cited 21 Nov 2017].
27. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, et al.
Clinical Implications of Phosphorylated STAT3 Expression in De Novo
Diffuse Large B-cell Lymphoma. Clin Cancer Res [Internet]. 2014;20(19)
Available from: http://clincancerres.aacrjournals.org/content/20/19/5113.
[cited 28 July 2017].
28. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic
active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature
[Internet]. 2010;463(7277):88–92 Available from: http://www.nature.com/
doifinder/10.1038/nature08638. [cited 21 Aug 2017].
29. Song TL, Nairismägi M-L, Laurensia Y, Lim J-Q, Tan J, Li Z-M, et al.
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in
natural killer/T-cell lymphoma. Blood [Internet]. 2018;132(11):1146–58
Available from: http://www.ncbi.nlm.nih.gov/pubmed/30054295. [cited 7
Oct 2018].
30. Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M,
et al. Mutations in the JAK/STAT pathway genes and activation of the
pathway, a relevant finding in nodal Peripheral T-cell lymphoma. Br J
Haematol [Internet]. 2017; Available from: http://www.ncbi.nlm.nih.gov/
pubmed/29076126. [cited 7 Oct 2018].
31. Nairismägi M-L, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y,
et al. Oncogenic activation of JAK3-STAT signaling confers clinical
sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in
natural killer/T-cell lymphoma. Leukemia [Internet]. 2018;32(5):1147–56
Available from: http://www.nature.com/articles/s41375-017-0004-x. [cited
7 Oct 2018].
32. Woessner R, Sah V, McCoon P, Grosskurth S, Deng N, DuPont R, et al.
Inhibition of STAT3 by antisense oligonucleotide treatment decreases the
immune suppressive tumor microenvironment in syngeneic and GEM
tumor models [abstract]. In: Proceedings of the 110th Annual Meeting of
the American Association for Cancer Research; 2017 Apr 1–5. Washington
DC and Philadephia: AACR; 2017. p. Abstract nr 3684.
33. Yang Z-Z, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, et al.
TGF-β upregulates CD70 expression and induces exhaustion of effector
memory T cells in B-cell non-Hodgkin’s lymphoma. Leukemia [Internet].
Reilley et al. Journal for ImmunoTherapy of Cancer           (2018) 6:119 Page 9 of 10
2014;28(9):1872–84 Available from: http://www.ncbi.nlm.nih.gov/pubmed/
24569779. [cited 7 Oct 2018].
34. Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, et al.
Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits
Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor
Cells. Clin Cancer Res [Internet]. 2017;23(2):587–99 Available from: http://
clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-0387.
[cited 21 Nov 2017].
35. Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A,
et al. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid
Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clin
Cancer Res [Internet]. 2016;22(23):5661–72 Available from: http://
clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-15-3104. [cited
21 Nov 2017].
36. Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, et al.
Tumor-expressed inducible nitric oxide synthase controls induction of
functional myeloid-derived suppressor cells through modulation of vascular
endothelial growth factor release. J Immunol [Internet]. 2012;188(11):5365–
76 Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.
1103553. [cited 21 Nov 2017].
37. Rosborough BR, Mathews LR, Matta BM, Liu Q, Raïch-Regué D, Thomson
AW, et al. Cutting edge: Flt3 ligand mediates STAT3-independent expansion
but STAT3-dependent activation of myeloid-derived suppressor cells. J
Immunol [Internet]. 2014;192(8):3470–3 Available from: http://www.
jimmunol.org/cgi/doi/10.4049/jimmunol.1300058. [cited 21 Nov 2017].
Reilley et al. Journal for ImmunoTherapy of Cancer           (2018) 6:119 Page 10 of 10
